Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV000002776 | SCV002779593 | pathogenic | Bardet-Biedl syndrome 9 | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000735941 | SCV003439923 | pathogenic | Bardet-Biedl syndrome | 2023-11-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg598*) in the BBS9 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS9 are known to be pathogenic (PMID: 16380913, 20177705). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 16380913, 30614526). ClinVar contains an entry for this variant (Variation ID: 2657). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000002776 | SCV004214219 | pathogenic | Bardet-Biedl syndrome 9 | 2022-09-13 | criteria provided, single submitter | clinical testing | |
Department of Clinical Genetics, |
RCV000002776 | SCV005414531 | pathogenic | Bardet-Biedl syndrome 9 | 2024-11-27 | criteria provided, single submitter | clinical testing | The stop variant causes Bardet-Biedl syndrome. |
Center for Genomic Medicine, |
RCV004813029 | SCV005438130 | likely pathogenic | Nephronophthisis 4 | 2024-12-17 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002776 | SCV000022934 | pathogenic | Bardet-Biedl syndrome 9 | 2005-12-01 | no assertion criteria provided | literature only | |
Laboratory of Medical Genetics |
RCV000735941 | SCV000839582 | pathogenic | Bardet-Biedl syndrome | 2018-09-15 | no assertion criteria provided | provider interpretation |